Iluvien Alternatives Compared
| Iluvien (fluocinolone) | Eylea (aflibercept) | Lucentis (ranibizumab) |
|
|---|
| Iluvien (fluocinolone) | Eylea (aflibercept) | Lucentis (ranibizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Diabetic Macular Edema, Uveitis - Posterior. Iluvien may also be used for purposes not listed in this medication guide. |
Prescription only
Eylea and Eylea HD both contain aflibercept and are VEGF (vascular endothelial growth factor) inhibitors that used to treat retinal eye diseases that may affect your vision. These include neovascular... View more |
Prescription only
Prescribed for Macular Degeneration, Myopic Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema, Macular Edema Following Retinal Vein Occlusion. Lucentis may... View more |
Related suggestions Diabetic Macular Edema
|
|||||||||||||||||||||||
| More about Iluvien (fluocinolone) | More about Eylea (aflibercept) | More about Lucentis (ranibizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Iluvien has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Eylea has an average rating of 7.1 out of 10 from a total of 74 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 19% reported a negative effect. |
Lucentis has an average rating of 6.1 out of 10 from a total of 15 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Iluvien side effects |
View all Eylea side effects |
View all Lucentis side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Iluvien prices |
View all Eylea prices |
View all Lucentis prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other fluocinolone brands include: Retisert, Yutiq | Other aflibercept brands include: Ahzantive, Enzeevu, Eylea HD, Opuviz, Pavblu, Yesafili | Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
144 hours |
216 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 8 drugs are known to interact with Iluvien:
|
A total of 1 drugs are known to interact with Eylea:
|
A total of 2 drugs are known to interact with Lucentis:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 26, 2014 |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vabysmo
Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-related macular ...
Eylea
Eylea is used to treat neovascular (wet) age-related macular degeneration (AMD), macular edema ...
Izervay
Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...
Eylea HD
Eylea HD is used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic ...
Lucentis
Lucentis is used to treat the wet form of age-related macular degeneration. Learn about side ...
Ozurdex
Ozurdex is an implant injected into the eye to treat swelling that may occur when there is a ...
Pavblu
Pavblu (aflibercept-ayyh) is a biosimilar to Eylea that may be used to treat the following eye ...
Maxidex
Maxidex is used for conjunctivitis, conjunctivitis, allergic, cyclitis, iritis, keratitis, macular ...
Yesafili
Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea that may be given by ...
Ranibizumab ophthalmic
Ranibizumab ophthalmic is used for diabetic macular edema, diabetic retinopathy, macular ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.